Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study Mahajan R, Singh A, Kedia S, Kaur K, , Sahu P, Mehta V, Singh D, Bansal N, Dharni K, Kaushal S, Ahuja V, Sood A Published Feb 2021, in the Intestinal research Abstract Background/aims: Infliximab (IFX) has been used to induce and maintain remission in patients with sever

Epidemiology of Inflammatory Bowel Diseases in Nepal Mukesh S. Paudel, Ajit Khanal, Barun Shrestha, Bibek Purbey, Bidhan N. Paudel, Gaurav Shrestha, Jiwan Thapa, Khus R. Dewan, Ram Gurung, Neeraj Joshi. Abstract Introduction Inflammatory bowel diseases (IBD) comprise ulcerative colitis (UC) and Crohn's disease (CD). These are diseases of the gastrointestinal tract without a clear etiology but have strong relationships with underlying factors like genetic susceptibility, envir

Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know? Shafiee NH, Manaf ZA, Mokhtar NM, Published Apr 2021, in the Intestinal research Abstract Current treatment for inflammatory bowel disease (IBD) includes the application of anti-inflammatory agents for the induction and remission of IBD. However, prolonged use of anti-inflammatory agents can exert adverse effects on patients. Recently, formulated dietary approach in treating IBD

The effects of extra virgin olive oil and canola oil on inflammatory markers and gastrointestinal symptoms in patients with ulcerative colitis Morvaridi M, Jafarirad S, Seyedian SS, , Cheraghian B. Published Jun 2020, in the European journal of clinical nutrition. Abstract Background/objectives: Ulcerative colitis (UC) is an immune-mediated disease that causes inflammation in the gastrointestinal tract. Diet has an important role in the treatment of UC. This study aimed to co

Antibiotic use differentially affects the risk of antidrug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN Yuri Gorelik ,Shay Freilich, Shiran Gerassy-Vainberg, Sigal Pressman, Chagit Friss, Alexandera Blatt, Gili Focht, Yiska Loewenberg Weisband, Shira Greenfeld, Revital Kariv, Nathan Lederman, Iris Dotan, Naama Geva-Zatorsky, Yechezkel Kashi, Shai Shlomo Shen-Orr, Yehuda Chowers, On behalf of the IIRN ABSTRACT O

Transethnic analysis of the human leukocyte antigen region for ulcerative colitis reveals not only shared but also ethnicity-specific disease associations Degenhardt F, Mayr G, Wendorff M, Boucher G, Ellinghaus E, Ellinghaus D, ElAbd H, Rosati E, Hübenthal M, Juzenas S, Abedian S, Vahedi H, Thelma BK, Yang SK, Ye BD, Cheon JH, Datta LW, Daryani NE, Ellul P, Esaki M, Fuyuno Y, McGovern DPB, Haritunians T, Hong M, Juyal G, Jung ES, Kubo M, Kugathasan S, Lenz TL, Leslie S, , Mid

Exclusive enteral nutrition is effective and feasible as primary induction and re-induction therapy in Asian children with Crohn's disease Chan KJ, Song ZL, Chew KS, Ng RT, Mohd Taib SH, Published Feb 2021, in the Journal of paediatrics and child health. Abstract Aim: We aimed to ascertain the efficacy and feasibility of exclusive enteral nutrition (EEN) as an induction and re-induction therapy in Asian children with Crohn's disease (CD). Methods: All children diagnosed with

Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial Vermeire S, Su C, Lawendy N, Kobayashi T, Sandborn WJ, Rubin DT, Modesto I, Gardiner S, Kulisek N, Zhang H, Wang W, Panés J Published Jul 2021, in the Journal of Crohn's & colitis. Abstract Background and aims: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We present primary completion analys

Dual Targeted Therapy for the Management of Inflammatory Bowel Disease Haider M, Lashner B Published Jul 2021, in the Journal of clinical gastroenterology. Abstract The burden of inflammatory bowel disease (IBD) is increasing globally and imposes a high morbidity in patients with IBD. Advances have been made in medical management of IBD with the advent of novel therapies such as the biologics and small molecule drugs (SMDs). However, response to these medications is limited;

Adjuvant use of combination of antibiotics in acute severe ulcerative colitis: A placebo controlled randomized trial Mishra S, Mandavdhare HS, Singh H, Choudhury A, Shah J, Ram S, Kalsi D, Samanta J, Prasad KK, Sharma AK, Dutta U, Sharma Published Jul 2021, in the Abstract Objectives: Evaluation of a combination of antibiotics as an adjuvant therapy in acute severe ulcerative colitis (ASUC). Methods: Patients with ASUC were randomized to either infusions of placebo or intrav

Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists Macaluso FS, Liguori G, Galli M. Published Jul 2021, in the Gastroenterology. Abstract Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, are chronic, progressive, immune-mediated diseases of adults and children that have no cure. IBD can cause significant morbidity and lead to complications such as

Effect of inflammatory bowel disease and related medications on COVID-19 incidence, disease severity, and outcome: the Israeli experience Richter V, Bermont A, Cohen DL, Broide E, Shirin H Published Jun 2021, in the European journal of gastroenterology & hepatology Abstract Objectives: The coronavirus disease 2019 (COVID-19) pandemic raised concerns among inflammatory bowel disease (IBD) patients fearing an increased risk of infection and poor outcomes. We aimed to evaluate t